<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROMETHAZINE DM- dextromethorphan hydrobromide and promethazine hydrochloride syrup </strong><br>Qualitest Pharmaceuticals<br></p></div>
<h1>PROMETHAZINE DM SYRUP<br> (PROMETHAZINE HYDROCHLORIDE, USP AND DEXTROMETHORPHAN HYDROBROMIDE, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d2ea7563-aa84-464f-826c-0b5a34e04fa7"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_fe1b1b4b-76ef-4a8c-b272-1290007c2d27"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each 5 mL (one teaspoonful), for oral administration contains: Dextromethorphan hydrobromide 15 mg; promethazine hydrochloride 6.25 mg.  Alcohol 7%.</p>
<p>Inactive Ingredients: Ascorbic acid, citric acid, D&amp;C yellow #10, FD&amp;C yellow #6, menthol, methylparaben, orange pineapple flavor, propylene glycol, propylparaben, purified water, saccharin sodium, sodium benzoate, sodium citrate and sucrose.</p>
<p>Dextromethorphan hydrobromide is a salt of the methyl ether of the dextrorotatory isomer of levorphanol, a narcotic analgesic. It is chemically designated as 3-methoxy-17-methyl-9α, 13α, 14α-morphinan hydrobromide monohydrate. Dextromethorphan hydrobromide occurs as white crystals sparingly soluble in water and freely soluble in alcohol. It has a molecular weight of 370.32, a molecular formula of C<span class="Sub">18</span>H<span class="Sub">25</span>NO•HBr•H<span class="Sub">2</span>O, and the following structural formula:</p>
<div class="Figure"><img alt="This is an image of the structural formula of Dextromethorphan" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c13f5f93-d291-4d0d-80fe-44dba4c5401e&amp;name=promethazinedmsyrp-1.jpg"></div>
<p>Promethazine is a racemic compound. Promethazine hydrochloride, a phenothiazine derivative, is chemically designated as 10<span class="Italics">H</span>-Phenothiazine-10-ethanamine, <span class="Italics">N</span>,<span class="Italics">N</span>, α-trimethyl-monohydrochloride.</p>
<p>Promethazine hydrochloride occurs as a white to <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> yellow, practically odorless, crystalline powder which slowly oxidizes and turns blue on prolonged exposure to air. It is soluble in water and freely soluble in alcohol. It has a molecular weight of 320.88, a molecular formula of C<span class="Sub">17</span>H<span class="Sub">20</span>N<span class="Sub">2</span>S•HCI, and the following structural formula:</p>
<div class="Figure"><img alt="This is an image of the structural formula of Promethazine" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c13f5f93-d291-4d0d-80fe-44dba4c5401e&amp;name=promethazinedmsyrp-2.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_292ad1d8-99dc-4f6a-91c1-4cc769a7e55f"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_76b31df3-3934-4f6c-9a75-602551b0c959"></a><a name="section-3.1"></a><p></p>
<h2>Dextromethorphan:</h2>
<p class="First">Dextromethorphan is an antitussive agent and, unlike the isomeric levorphanol, it has no analgesic or addictive properties.</p>
<p>The drug acts centrally and elevates the threshold for <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>. It is about equal to codeine in depressing the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex. In therapeutic dosage dextromethorphan does not inhibit ciliary activity.</p>
<p>Dextromethorphan is rapidly absorbed from the gastrointestinal tract and exerts its effect in 15 to 30 minutes. The duration of action after oral administration is approximately three to six hours. Dextromethorphan is metabolized primarily by liver enzymes undergoing O-demethylation, N-demethylation, and partial conjugation with glucuronic acid and sulfate. In humans, (+)-3-hydroxy-N-methyl-morphinan, (+)-3-hydroxymorphinan, and traces of unmetabolized drug were found in urine after oral administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_15924b41-ce22-434c-8f42-fca828902d9e"></a><a name="section-3.2"></a><p></p>
<h2>Promethazine:</h2>
<p class="First">Promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. It is thought that this configuration is responsible for its relative lack (1/10 that of chlorpromazine) of dopamine antagonist properties.</p>
<p>Promethazine is an H<span class="Sub">1</span> receptor blocking agent. In addition to its antihistaminic action, it provides clinically useful sedative and antiemetic effects.</p>
<p>Promethazine is well absorbed from the gastrointestinal tract. Clinical effects are apparent within 20 minutes after oral administration and generally last four to six hours, although they may persist as long as 12 hours. Promethazine is metabolized by the liver to a variety of compounds; the sulfoxides of promethazine and N-demethylpromethazine are the predominant metabolites appearing in the urine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_8e277f6d-d081-4251-a793-500df857122b"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Promethazine hydrochloride and dextromethorphan hydrobromide syrup is indicated for the temporary relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughs</span> and upper respiratory symptoms associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_b88724ce-fd13-4a98-beea-f9559c487fbd"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Dextromethorphan should not be used in patients receiving a monoamine oxidase inhibitor (MAOI) (see <span class="Bold"><a href="#LINK_b47e6f0f-6c1e-47a5-abf7-690cb236fbe9">PRECAUTIONS,</a></span><span class="Bold"><a href="#LINK_67a897e2-ac3b-4179-9579-387a56fe4a13">Drug Interactions</a></span>).</p>
<p>Promethazine is contraindicated in <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines.</p>
<p>Antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms, including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_b072a10c-eba5-4c75-8266-0b1e5b7dc3d4"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Warning">
<a name="LINK_9fb8a11f-46ab-4cb6-b12c-0fde3be858d0"></a><a name="section-6.1"></a><p></p>
<h2></h2>
<p class="First">WARNING:</p>
<p>PROMETHAZINE HYDROCHLORIDE SHOULD NOT BE USED IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE BECAUSE OF THE POTENTIAL FOR FATAL <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>.</p>
<p>POSTMARKETING CASES OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, INCLUDING FATALITIES, HAVE BEEN REPORTED WITH USE OF PROMETHAZINE HYDROCHLORIDE IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE. A WIDE RANGE OF WEIGHT-BASED DOSES OF PROMETHAZINE HYDROCHLORIDE HAVE RESULTED IN <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> IN THESE PATIENTS.</p>
<p>CAUTION SHOULD BE EXERCISED WHEN ADMINISTERING PROMETHAZINE HYDROCHLORIDE TO PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER. IT IS RECOMMENDED THAT THE LOWEST EFFECTIVE DOSE OF PROMETHAZINE HYDROCHLORIDE BE USED IN PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER AND CONCOMITANT ADMINISTRATION OF OTHER DRUGS WITH RESPIRATORY DEPRESSANT EFFECTS BE AVOIDED.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d3b83a1a-64b3-4be1-af4b-3c314038d5c9"></a><a name="section-6.1"></a><p></p>
<h2>Dextromethorphan:</h2>
<p class="First">Administration of dextromethorphan may be accompanied by histamine release and should be used with caution in <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopic</span> children.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_46554f9c-10a1-460e-8c46-3def1cbfcd6b"></a><a name="section-6.2"></a><p></p>
<h2>Promethazine:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1c14a452-71a3-411f-9900-4e2db710f9d2"></a><a name="section-6.2.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS Depression</span></h3>
<p class="First">Promethazine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a vehicle or operating machinery. The impairment may be amplified by concomitant use of other central nervous system depressants such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should either be eliminated or given in reduced dosage in the presence of promethazine HCl (see <span class="Bold"><a href="#LINK_b47e6f0f-6c1e-47a5-abf7-690cb236fbe9">PRECAUTIONS -</a></span><span class="Bold"><a href="#LINK_15b77f9c-9b9e-43f0-a9c1-a41ccbebf175">Information For Patients</a></span> and <span class="Bold"><a href="#LINK_67a897e2-ac3b-4179-9579-387a56fe4a13">Drug Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ddc82ce0-9af0-495e-b54e-f6b3e9656ab2"></a><a name="section-6.2.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h3>
<p class="First">Promethazine may lead to potentially fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p>Use of promethazine in patients with compromised respiratory function (e.g., <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>) should be avoided.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6b1fca8d-d601-4afa-9b75-f20107987970"></a><a name="section-6.2.3"></a><p></p>
<h3>Lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Threshold</h3>
<p class="First">Promethazine may lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. It should be used with caution in persons with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders or in persons who are using concomitant medications, such as narcotics or local anesthetics, which may also affect <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_29e87c89-f8b9-4790-8afb-518c77af2d1f"></a><a name="section-6.2.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Bone Marrow Depression</span></h3>
<p class="First">Promethazine should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported, usually when promethazine HCl has been used in association with other known marrow toxic agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ebaf2652-1bb5-48f2-93d4-89fbf741ed24"></a><a name="section-6.2.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></h3>
<p class="First">A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with promethazine HCl alone or in combination with antipsychotic drugs. Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>).</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span> and primary central nervous system (CNS) pathology.</p>
<p>The management of NMS should include 1) immediate discontinuation of promethazine HCl, antipsychotic drugs, if any, and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.</p>
<p>Since recurrences of NMS have been reported with phenothiazines, the reintroduction of promethazine HCl should be carefully considered.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_a95a84ea-b913-4b4e-8804-5f5f7bede09f"></a><a name="section-7"></a><p></p>
<h1>Use In Pediatric Patients</h1>
<p class="First"><span class="Bold">PROMETHAZINE PRODUCTS ARE CONTRAINDICATED FOR USE IN PEDIATRIC PATIENTS LESS THAN TWO YEARS OF AGE.</span></p>
<p><span class="Bold">CAUTION SHOULD BE EXERCISED WHEN ADMINISTERING PROMETHAZINE PRODUCTS TO PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER BECAUSE OF THE POTENTIAL FOR FATAL <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> AND <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">APNEA</span>, SOMETIMES ASSOCIATED WITH <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>, ARE STRONGLY ASSOCIATED WITH PROMETHAZINE PRODUCTS AND ARE NOT DIRECTLY RELATED TO INDIVIDUALIZED WEIGHT-BASED DOSING, WHICH MIGHT OTHERWISE PERMIT SAFE ADMINISTRATION. CONCOMITANT ADMINISTRATION OF PROMETHAZINE PRODUCTS WITH OTHER RESPIRATORY DEPRESSANTS HAS AN ASSOCIATION WITH <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, AND SOMETIMES <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>, IN PEDIATRIC PATIENTS.</span></p>
<p><span class="Bold">ANTIEMETICS ARE NOT RECOMMENDED FOR TREATMENT OF UNCOMPLICATED <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> IN PEDIATRIC PATIENTS, AND THEIR USE SHOULD BE LIMITED TO PROLONGED <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> OF KNOWN ETIOLOGY. THE <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">EXTRAPYRAMIDAL SYMPTOMS</span> WHICH CAN OCCUR SECONDARY TO PROMETHAZINE HYDROCHLORIDE ADMINISTRATION MAY BE <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">CONFUSED</span> WITH THE CNS SIGNS OF UNDIAGNOSED PRIMARY DISEASE, e.g., <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">ENCEPHALOPATHY</span> OR REYE'S SYNDROME. THE USE OF PROMETHAZINE PRODUCTS SHOULD BE AVOIDED IN PEDIATRIC PATIENTS WHOSE SIGNS AND SYMPTOMS MAY SUGGEST REYE'S SYNDROME OR OTHER <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">HEPATIC DISEASES</span>.</span></p>
<p>Excessively large dosages of antihistamines, including promethazine hydrochloride, in pediatric patients may cause <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> (see <span class="Bold"><a href="#LINK_d4ad5ec9-de5d-4429-b592-f331607950cc">OVERDOSAGE</a></span>). <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> have occurred with therapeutic doses and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of promethazine hydrochloride in pediatric patients. In pediatric patients who are acutely ill associated with <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, there is an increased susceptibility to <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonias</span> with the use of promethazine HCl.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b3fe1d6e-7fb9-4a67-84b1-427a506759e0"></a><a name="section-8"></a><p></p>
<h1>Other Considerations</h1>
<p class="First">Administration of promethazine has been associated with reported <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_b47e6f0f-6c1e-47a5-abf7-690cb236fbe9"></a><a name="section-9"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Animal reproduction studies have not been conducted with the drug combination–promethazine and dextromethorphan. It is not known whether this drug combination can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Promethazine and dextromethorphan should be given to a pregnant woman only if clearly needed.</p>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_68936d4e-c0cb-43d5-9957-cc450bb4b014"></a><a name="section-9.1"></a><p></p>
<h2>General:</h2>
<p class="First">Dextromethorphan should be used with caution in sedated patients, in the debilitated, and in patients confined to the supine position.</p>
<p>Drugs having anticholinergic properties should be used with caution in patients with narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, stenosing <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, pyloroduodenal obstruction, and bladder-neck obstruction.</p>
<p>Promethazine should be used cautiously in persons with cardiovascular disease or with impairment of liver function.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_15b77f9c-9b9e-43f0-a9c1-a41ccbebf175"></a><a name="section-9.2"></a><p></p>
<h2>Information For Patients:</h2>
<p class="First">Promethazine and dextromethorphan may cause marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a vehicle or operating machinery. Ambulatory patients should be told to avoid engaging in such activities until it is known that they do not become drowsy or dizzy from promethazine and dextromethorphan therapy. Children should be supervised to avoid potential harm in bike riding or in other hazardous activities.</p>
<p>The concomitant use of alcohol or other central nervous system depressants, including narcotic analgesics, sedatives, hypnotics, and tranquilizers, may have an additive effect and should be avoided or their dosage reduced.</p>
<p>Patients should be advised to report any <span class="product-label-link" type="condition" conceptid="4319906" conceptname="Dyskinesia">involuntary muscle movements</span>.</p>
<p>Avoid prolonged exposure to the sun.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_67a897e2-ac3b-4179-9579-387a56fe4a13"></a><a name="section-9.3"></a><p></p>
<h2>Drug Interactions:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_108a9c7d-8d2c-4305-b0b7-99043448a4b0"></a><a name="section-9.3.1"></a><p></p>
<h3>Dextromethorphan:</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported coincident with the coadministration of monoamine oxidase (MAO) inhibitors and products containing dextromethorphan. Thus, concomitant administration of promethazine with dextromethorphan and MAO inhibitors should be avoided (see <span class="Bold"><a href="#LINK_b88724ce-fd13-4a98-beea-f9559c487fbd">CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_50ca353b-b412-4b73-aa2d-230f035fd778"></a><a name="section-9.3.2"></a><p></p>
<h3>Promethazine:</h3>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2e5d5373-741e-4ba1-9e2b-72cd84f994ba"></a><a name="section-9.3.3"></a><p></p>
<h3><span class="Italics">CNS Depressants – </span></h3>
<p class="First">Promethazine may increase, prolong, or intensify the sedative action of other central nervous system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine HCl. When given concomitantly with promethazine, the dose of barbiturates should be reduced by at least one-half, and the dose of narcotics should be reduced by one-quarter to one-half. Dosage must be individualized. Excessive amounts of promethazine HCl relative to a narcotic may lead to <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and motor <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> in the patient with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; these symptoms usually disappear with adequate control of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ab97dcd8-8e37-4367-a98a-bb0ed38e3fc7"></a><a name="section-9.3.4"></a><p></p>
<h3><span class="Italics">Epinephrine – </span></h3>
<p class="First">Because of the potential for promethazine to reverse epinephrine's vasopressor effect, epinephrine should NOT be used to treat <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> associated with promethazine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0866c90f-0170-4ff9-927f-91a1a4c8afc3"></a><a name="section-9.3.5"></a><p></p>
<h3><span class="Italics">Anticholinergics – </span></h3>
<p class="First">Concomitant use of other agents with anticholinergic properties should be undertaken with caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8f0731ca-46d7-4c90-b7d9-1f83b13c569b"></a><a name="section-9.3.6"></a><p></p>
<h3><span class="Italics">Monoamine Oxidase Inhibitors (MAOI) – </span></h3>
<p class="First">Drug interactions, including an increased incidence of extrapyramidal effects, have been reported when some MAOI and phenothiazines are used concomitantly.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_adc54adb-76df-430d-9a5b-51b57b4a1abc"></a><a name="section-9.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions:</h2>
<p class="First">The following laboratory tests may be affected in patients who are receiving therapy with promethazine hydrochloride.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_efd0e20d-815b-4b4b-91d6-f414a825ef79"></a><a name="section-9.4.1"></a><p></p>
<h3>Pregnancy Tests:</h3>
<p class="First">Diagnostic pregnancy tests based on immunological reactions between HCG and anti-HCG may result in false-negative or false-positive interpretations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_eb05af11-1d1b-4f57-9d75-79f9642b92b5"></a><a name="section-9.4.2"></a><p></p>
<h3>Glucose Tolerance Test:</h3>
<p class="First">An increase in blood glucose has been reported in patients receiving promethazine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_90f9fe9e-b133-465f-b105-7f4149c3bffd"></a><a name="section-9.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment Of Fertility:</h2>
<p class="First">Long-term animal studies have not been performed to assess the carcinogenic potential of promethazine or of dextromethorphan. There are no animal or human data concerning the carcinogenicity, mutagenicity, or impairment of fertility with these drugs. Promethazine was nonmutagenic in the <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span>  test system of Ames.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_9cfeec71-eadf-4cf0-a621-9c7149c9f2bd"></a><a name="section-9.6"></a><p></p>
<h2>Pregnancy:</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_d8078d9c-39e5-4809-a262-88139848f0cd"></a><a name="section-9.6.1"></a><p></p>
<h3>Teratogenic Effects – <span class="Italics">Pregnancy Category C:</span>
</h3>
<p class="First">Teratogenic effects have not been demonstrated in rat-feeding studies at doses of 6.25 and 12.5 mg/kg of promethazine HCl. These doses are from approximately 2.1 to 4.2 times the maximum recommended total daily dose of promethazine for a 50-kg subject, depending upon the indication for which the drug is prescribed. Daily doses of 25 mg/kg intraperitoneally have been found to produce fetal mortality in rats.</p>
<p>Specific studies to test the action of the drug on parturition, lactation, and development of the animal neonate were not done, but a general preliminary study in rats indicated no effect on these parameters.  Although antihistamines have been found to produce fetal mortality in rodents, the pharmacological effects of histamine in the rodent do not parallel those in man. There are no adequate and well-controlled studies of promethazine in pregnant women.</p>
<p>Promethazine and dextromethorphan should be used during pregnancy only if the potential benefit justifies the risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="LINK_66708503-078c-4a8c-b9b8-966f33d1f47f"></a><a name="section-9.6.2"></a><p></p>
<h3>Nonteratogenic Effects:</h3>
<p class="First">Promethazine administered to a pregnant woman within two weeks of delivery may inhibit platelet aggregation in the newborn.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_8e0cd4ac-e0fd-44ad-8304-0c985b85525a"></a><a name="section-9.7"></a><p></p>
<h2>Labor And Delivery:</h2>
<p class="First">Limited data suggest that use of promethazine HCl during labor and delivery does not have an appreciable effect on the duration of labor or delivery and does not increase the risk of need for intervention in the newborn. The effect on later growth and development of the newborn is unknown. 
								See also "<a href="#LINK_66708503-078c-4a8c-b9b8-966f33d1f47f">Nonteratogenic Effects </a>".</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_bb49fdae-4db5-43ca-bdc6-19d6d5bab4e5"></a><a name="section-9.8"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether promethazine or dextromethorphan is excreted in human milk.</p>
<p>Caution should be exercised when promethazine and dextromethorphan is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_5a1da2c1-a7e8-424a-9c66-b90e9f9fe09e"></a><a name="section-9.9"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First"><span class="Bold">PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE SYRUP IS CONTRAINDICATED FOR USE IN PEDIATRIC PATIENTS LESS THAN TWO YEARS OF AGE </span>(see <span class="Bold"><a href="#LINK_b072a10c-eba5-4c75-8266-0b1e5b7dc3d4">WARNINGS –</a></span><span class="Bold"><a href="#LINK_9fb8a11f-46ab-4cb6-b12c-0fde3be858d0">Black Box Warning</a></span> and <span class="Bold"><a href="#LINK_a95a84ea-b913-4b4e-8804-5f5f7bede09f">Use In Pediatric Patients</a></span>).</p>
<p>Promethazine hydrochloride and dextromethorphan hydrobromide syrup should be used with caution in pediatric patients 2 years of age and older (see <span class="Bold"><a href="#LINK_b072a10c-eba5-4c75-8266-0b1e5b7dc3d4">WARNINGS –</a></span><span class="Bold"><a href="#LINK_a95a84ea-b913-4b4e-8804-5f5f7bede09f">Use In Pediatric Patients</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_f1c7ec20-f8ae-4d7e-bfaa-312caccbe704"></a><a name="section-9.10"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">Clinical studies of promethazine hydrochloride and dextromethorphan hydrobromide syrup did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>Sedating drugs may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and over-sedation in the elderly; elderly patients generally should be started on low doses of promethazine hydrochloride and dextromethorphan hydrobromide syrup and observed closely.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_c06ea243-1b83-46f5-a5bd-01cb0d51f3c9"></a><a name="section-10"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Dextromethorphan:</span></p>
<p>Dextromethorphan hydrobromide occasionally causes slight <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>.</p>
<p><span class="Bold">Promethazine:</span></p>
<p>Central Nervous System – <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> is the most prominent CNS effect of this drug. Sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> such as <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, and tongue protrusion; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>, excitation, <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonic</span>-like states, <span class="product-label-link" type="condition" conceptid="434889" conceptname="Dissociative disorder">hysteria</span>. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> have also been reported.</p>
<p>Cardiovascular – Increased or decreased blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, faintness.</p>
<p>Dermatologic – <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Hematologic – <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p>Gastrointestinal – <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
<p>Respiratory – <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (potentially fatal) and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> (potentially fatal). (See <span class="Bold"><a href="#LINK_b072a10c-eba5-4c75-8266-0b1e5b7dc3d4">WARNINGS –</a></span><span class="Bold"><a href="#LINK_46554f9c-10a1-460e-8c46-3def1cbfcd6b">Promethazine; </a></span><a href="#LINK_ddc82ce0-9af0-495e-b54e-f6b3e9656ab2"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a>.)</p>
<p>Other – <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioneurotic edema</span>. <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic malignant syndrome</span> (potentially fatal) has also been reported. (See <span class="Bold"><a href="#LINK_b072a10c-eba5-4c75-8266-0b1e5b7dc3d4">WARNINGS –</a></span><span class="Bold"><a href="#LINK_46554f9c-10a1-460e-8c46-3def1cbfcd6b">Promethazine; </a></span><a href="#LINK_ebaf2652-1bb5-48f2-93d4-89fbf741ed24"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></a>.)</p>
<p>Paradoxical Reactions – <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Hyperexcitability</span> and abnormal movements have been reported in patients following a single administration of promethazine HCl. Consideration should be given to the discontinuation of promethazine HCl and to the use of other drugs if these reactions occur. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> behavior have also been reported in some of these patients.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_1eb2c9a8-c4a1-46bc-97ce-2a2fd0758d67"></a><a name="section-11"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">According to the WHO Expert Committee on <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span>, dextromethorphan could produce very slight psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> but no physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_d4ad5ec9-de5d-4429-b592-f331607950cc"></a><a name="section-12"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c0a447c1-5730-4706-bc7d-8f90869ac9f7"></a><a name="section-12.1"></a><p></p>
<h2>Dextromethorphan:</h2>
<p class="First">Dextromethorphan may produce central <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>. Very high doses may produce <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. One case of toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (<span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, marked visual and <span class="product-label-link" type="condition" conceptid="4164151" conceptname="Auditory hallucinations">auditory hallucinations</span>) after ingestion of a single dose of 20 tablets (300 mg) of dextromethorphan has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ddc76563-74e2-4ad0-a230-1921930951c8"></a><a name="section-12.2"></a><p></p>
<h2>Promethazine:</h2>
<p class="First">Signs and symptoms of overdosage with promethazine HCl range from mild <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the central nervous system and cardiovascular system to profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. Other reported reactions include <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4259277" conceptname="Athetosis">athetosis</span>, and extensor-plantar reflexes (Babinski reflex).</p>
<p>Stimulation may be evident, especially in children and geriatric patients.  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> may rarely occur. A paradoxical reaction has been reported in children receiving single doses of 75 mg to 125 mg orally, characterized by <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">hyperexcitability</span> and <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>.</p>
<p>Atropine-like signs and symptoms – <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4011326" conceptname="Fixed dilatation of pupil">fixed dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, as well as <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, may occur.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2e82512e-13e6-4c60-8425-7cde3107af11"></a><a name="section-12.2.1"></a><p></p>
<h3>Treatment:</h3>
<p class="First">The treatment of overdosage with promethazine and dextromethorphan is essentially symptomatic and supportive. Only in cases of extreme overdosage or individual sensitivity do vital signs including respiration, pulse, blood pressure, temperature, and EKG need to be monitored. Activated charcoal orally or by lavage may be given, or sodium or magnesium sulfate orally as a cathartic. Attention should be given to the re-establishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. Diazepam may be used to control <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span> and electrolyte losses should be corrected. The antidotal efficacy of narcotic antagonists to dextromethorphan has not been established; note that any of the depressant effects of promethazine are not reversed by naloxone. Avoid analeptics, which may cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> usually responds to the administration of norepinephrine or phenylephrine. EPINEPHRINE SHOULD NOT BE USED, since its use in a patient with partial adrenergic blockage may further lower the blood pressure.</p>
<p>Limited experience with dialysis indicates that it is not helpful.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_8eed3e79-475a-4cad-92f6-0b4aee751291"></a><a name="section-13"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Promethazine hydrochloride and dextromethorphan hydrobromide syrup is contraindicated for children under 2 years of age</span> (see <span class="Bold"><a href="#LINK_b072a10c-eba5-4c75-8266-0b1e5b7dc3d4">WARNINGS –</a></span><span class="Bold"><a href="#LINK_9fb8a11f-46ab-4cb6-b12c-0fde3be858d0">Black Box Warning</a></span> and <span class="Bold"><a href="#LINK_a95a84ea-b913-4b4e-8804-5f5f7bede09f">Use In Pediatric Patients</a></span>).</p>
<p>The average effective dose is given in the following table:</p>
<table>
<col width="40%">
<col width="60%">
<tbody class="Headless">
<tr class="First">
<td> <br>Adults</td>
<td> <br><br>1 teaspoonful (5 mL) every 4 to 6 hours, <br>not to exceed 30 mL in 24 hours.</td>
</tr>
<tr>
<td> <br>Children 6 Years To Under 12 Years</td>
<td> <br><br>½ to 1 teaspoonful (2.5 to 5 mL) every 4 to 6 hours, <br>not to exceed 20 mL in 24 hours.</td>
</tr>
<tr class="Last">
<td> <br>Children 2 Years To Under 6 Years</td>
<td> <br><br>¼ to ½ teaspoonful (1.25 to 2.5 mL) every 4 to 6 hours, <br>not to exceed 10 mL in 24 hours.</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_7f2603ba-283c-4e90-a3cd-b2237451aa76"></a><a name="section-14"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">This preparation is a clear syrup with yellow color and pineapple menthol odor, containing promethazine hydrochloride 6.25 mg/5 mL, dextromethorphan hydrobromide 15 mg/5 mL and alcohol 7 percent, and is available in 4 fluid ounce (118 mL), 8 fluid ounce (237 mL) and one pint (473 mL).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_db8505fd-6ada-46fc-b2ed-a86e66a8cc73"></a><a name="section-14.1"></a><p></p>
<h2></h2>
<p class="First">Keep tightly closed. Protect from light.</p>
<p>Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container with a child-resistant closure as defined in the USP.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_dd7a8b49-b910-4ee6-87b4-331657acd555"></a><a name="section-15"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:<br><span class="Bold">QUALITEST PHARMACEUTICALS</span><br>Huntsville, AL 35811</p>
<p>8181650<br>R12/07-R1</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_d9734e95-ccea-408c-84fe-cef34247898f"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="This is an image of the label for Promethazine DM Syrup 473 mL." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c13f5f93-d291-4d0d-80fe-44dba4c5401e&amp;name=promethazinedmsyrp-3.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROMETHAZINE DM 		
					</strong><br><span class="contentTableReg">dextromethorphan hydrobromide and promethazine hydrochloride syrup</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0603-1586</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROMETHORPHAN HYDROBROMIDE</strong> (DEXTROMETHORPHAN) </td>
<td class="formItem">DEXTROMETHORPHAN HYDROBROMIDE</td>
<td class="formItem">15 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PROMETHAZINE HYDROCHLORIDE</strong> (PROMETHAZINE) </td>
<td class="formItem">PROMETHAZINE HYDROCHLORIDE</td>
<td class="formItem">6.25 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASCORBIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MENTHOL, UNSPECIFIED FORM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (Clear-Yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">ORANGE (Orange-Pineapple) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0603-1586-54</td>
<td class="formItem">118 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0603-1586-56</td>
<td class="formItem">237 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0603-1586-58</td>
<td class="formItem">473 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040649</td>
<td class="formItem">02/14/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Qualitest Pharmaceuticals
							(011103059)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Vintage Pharmaceuticals-Huntsville</td>
<td class="formItem"></td>
<td class="formItem">825839835</td>
<td class="formItem">MANUFACTURE(0603-1586)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>86b0bf88-3c6e-4dae-9a97-21be6494e382</div>
<div>Set id: c13f5f93-d291-4d0d-80fe-44dba4c5401e</div>
<div>Version: 4</div>
<div>Effective Time: 20150205</div>
</div>
</div> <div class="DistributorName">Qualitest Pharmaceuticals</div></p>
</body></html>
